Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel

Historical Valuation Ratios (Summary)

Celgene Corp., historical price multiples (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Price to earnings (P/E) 13.08 12.45 13.96 15.57 17.58 22.20 22.07 24.35 22.82 39.86 45.43 44.99 38.09 44.78 47.48 48.59 57.19 48.72 35.14 49.41
Price to operating profit (P/OP) 9.74 8.98 9.91 12.13 11.10 15.58 16.52 15.21 17.73 27.87 29.53 28.40 25.88 30.74 33.35 34.53 44.94 40.05 28.42 39.23
Price to sales (P/S) 4.53 4.01 4.20 4.13 3.46 4.40 4.65 5.52 6.31 8.63 8.31 8.04 7.55 8.55 8.33 8.50 10.91 12.87 10.83 13.06
Price to book value (P/BV) 6.36 6.53 8.11 10.22 10.46 18.11 12.18 10.34 7.99 12.43 12.66 13.63 14.37 15.54 15.76 13.15 17.61 16.93 12.67 15.14 14.64 14.46 13.10

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Celgene Corp. P/E ratio decreased from Q1 2019 to Q2 2019 but then slightly increased from Q2 2019 to Q3 2019.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Celgene Corp. P/OP ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 not reaching Q1 2019 level.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Celgene Corp. P/S ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Celgene Corp. P/BV ratio decreased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Price to Earnings (P/E)

Celgene Corp., historical P/E calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 711,714,480 708,741,260 705,259,536 702,164,345 699,251,840 703,363,010 724,827,113 752,175,608 787,316,931 782,350,672 780,824,335 777,966,471 775,203,498 775,114,702 774,601,496 781,664,535 785,654,567 790,540,158 793,144,382 800,590,656 798,704,188 799,510,100 800,833,654
Selected Financial Data (US$)
Net income (loss) (in millions) 1,691 1,571 1,545 1,073 1,082 1,045 846 (81) 988 1,101 932 429 171 598 801 561 (34) 356 719 614 509 598 280
Earnings per share (EPS)2 8.26 7.44 6.73 5.76 4.14 3.98 3.94 3.91 4.38 3.37 2.73 2.57 2.75 2.48 2.17 2.05 2.11 2.78 3.08 2.50 0.00 0.00 0.00
Share price1, 3 108.03 92.61 93.92 89.71 72.72 88.31 86.89 95.16 99.99 134.15 123.97 115.61 104.72 111.26 103.22 99.59 120.46 135.42 108.06 123.43 105.70 87.73 73.35
Valuation Ratio
P/E ratio4 13.08 12.45 13.96 15.57 17.58 22.20 22.07 24.35 22.82 39.86 45.43 44.99 38.09 44.78 47.48 48.59 57.19 48.72 35.14 49.41
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
EPS = (Net income (loss)Q3 2019 + Net income (loss)Q2 2019 + Net income (loss)Q1 2019 + Net income (loss)Q4 2018) ÷ No. shares of common stock outstanding
= (1,691,000,000 + 1,571,000,000 + 1,545,000,000 + 1,073,000,000) ÷ 711,714,480 = 8.26

3 Closing price as at the filing date of Celgene Corp. Quarterly or Annual Report.

4 Q3 2019 Calculation
P/E ratio = Share price ÷ EPS
= 108.03 ÷ 8.26 = 13.08

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. Celgene Corp. P/E ratio decreased from Q1 2019 to Q2 2019 but then slightly increased from Q2 2019 to Q3 2019.

Price to Operating Profit (P/OP)

Celgene Corp., historical P/OP calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 711,714,480 708,741,260 705,259,536 702,164,345 699,251,840 703,363,010 724,827,113 752,175,608 787,316,931 782,350,672 780,824,335 777,966,471 775,203,498 775,114,702 774,601,496 781,664,535 785,654,567 790,540,158 793,144,382 800,590,656 798,704,188 799,510,100 800,833,654
Selected Financial Data (US$)
Operating income (in millions) 2,264 2,111 1,710 1,807 1,680 1,486 218 1,198 1,085 1,311 1,113 930 412 824 1,002 900 80 416 859 752 647 759 362
Operating profit per share2 11.09 10.31 9.48 7.39 6.55 5.67 5.26 6.26 5.64 4.81 4.20 4.07 4.05 3.62 3.09 2.88 2.68 3.38 3.80 3.15 0.00 0.00 0.00
Share price1, 3 108.03 92.61 93.92 89.71 72.72 88.31 86.89 95.16 99.99 134.15 123.97 115.61 104.72 111.26 103.22 99.59 120.46 135.42 108.06 123.43 105.70 87.73 73.35
Valuation Ratio
P/OP ratio4 9.74 8.98 9.91 12.13 11.10 15.58 16.52 15.21 17.73 27.87 29.53 28.40 25.88 30.74 33.35 34.53 44.94 40.05 28.42 39.23
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
Operating profit per share = (Operating incomeQ3 2019 + Operating incomeQ2 2019 + Operating incomeQ1 2019 + Operating incomeQ4 2018) ÷ No. shares of common stock outstanding
= (2,264,000,000 + 2,111,000,000 + 1,710,000,000 + 1,807,000,000) ÷ 711,714,480 = 11.09

3 Closing price as at the filing date of Celgene Corp. Quarterly or Annual Report.

4 Q3 2019 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 108.03 ÷ 11.09 = 9.74

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. Celgene Corp. P/OP ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 not reaching Q1 2019 level.

Price to Sales (P/S)

Celgene Corp., historical P/S calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 711,714,480 708,741,260 705,259,536 702,164,345 699,251,840 703,363,010 724,827,113 752,175,608 787,316,931 782,350,672 780,824,335 777,966,471 775,203,498 775,114,702 774,601,496 781,664,535 785,654,567 790,540,158 793,144,382 800,590,656 798,704,188 799,510,100 800,833,654
Selected Financial Data (US$)
Net product sales (in millions) 4,518 4,399 4,024 4,036 3,890 3,808 3,531 3,479 3,283 3,259 2,952 2,977 2,969 2,745 2,495 2,539 2,313 2,254 2,055 2,055 1,957 1,845 1,708
Sales per share2 23.85 23.07 22.34 21.74 21.03 20.05 18.70 17.25 15.84 15.54 14.91 14.38 13.86 13.02 12.39 11.72 11.04 10.53 9.97 9.45 0.00 0.00 0.00
Share price1, 3 108.03 92.61 93.92 89.71 72.72 88.31 86.89 95.16 99.99 134.15 123.97 115.61 104.72 111.26 103.22 99.59 120.46 135.42 108.06 123.43 105.70 87.73 73.35
Valuation Ratio
P/S ratio4 4.53 4.01 4.20 4.13 3.46 4.40 4.65 5.52 6.31 8.63 8.31 8.04 7.55 8.55 8.33 8.50 10.91 12.87 10.83 13.06
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
Sales per share = (Net product salesQ3 2019 + Net product salesQ2 2019 + Net product salesQ1 2019 + Net product salesQ4 2018) ÷ No. shares of common stock outstanding
= (4,518,000,000 + 4,399,000,000 + 4,024,000,000 + 4,036,000,000) ÷ 711,714,480 = 23.85

3 Closing price as at the filing date of Celgene Corp. Quarterly or Annual Report.

4 Q3 2019 Calculation
P/S ratio = Share price ÷ Sales per share
= 108.03 ÷ 23.85 = 4.53

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Celgene Corp. P/S ratio decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.

Price to Book Value (P/BV)

Celgene Corp., historical P/BV calculation (quarterly data)

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
No. shares of common stock outstanding1 711,714,480 708,741,260 705,259,536 702,164,345 699,251,840 703,363,010 724,827,113 752,175,608 787,316,931 782,350,672 780,824,335 777,966,471 775,203,498 775,114,702 774,601,496 781,664,535 785,654,567 790,540,158 793,144,382 800,590,656 798,704,188 799,510,100 800,833,654
Selected Financial Data (US$)
Stockholders’ equity (in millions) 12,087 10,051 8,165 6,161 4,860 3,430 5,172 6,921 9,850 8,445 7,644 6,599 5,650 5,549 5,075 5,919 5,376 6,322 6,765 6,525 5,768 4,851 4,485
Book value per share (BVPS)2 16.98 14.18 11.58 8.77 6.95 4.88 7.14 9.20 12.51 10.79 9.79 8.48 7.29 7.16 6.55 7.57 6.84 8.00 8.53 8.15 7.22 6.07 5.60
Share price1, 3 108.03 92.61 93.92 89.71 72.72 88.31 86.89 95.16 99.99 134.15 123.97 115.61 104.72 111.26 103.22 99.59 120.46 135.42 108.06 123.43 105.70 87.73 73.35
Valuation Ratio
P/BV ratio4 6.36 6.53 8.11 10.22 10.46 18.11 12.18 10.34 7.99 12.43 12.66 13.63 14.37 15.54 15.76 13.15 17.61 16.93 12.67 15.14 14.64 14.46 13.10
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc.
Amgen Inc. 11.47 10.37 9.92
Bristol-Myers Squibb Co. 5.30 4.63 4.91
Eli Lilly & Co. 31.28 39.03 46.37
Gilead Sciences Inc. 4.02 3.58 3.83
Johnson & Johnson 5.84 5.78 6.39
Merck & Co. Inc. 7.87 7.82 7.31
Pfizer Inc. 3.14 3.42 3.84
Regeneron Pharmaceuticals Inc. 3.48 3.38 3.74
Thermo Fisher Scientific Inc. 4.15 3.83 4.02
Vertex Pharmaceuticals Inc. 9.57 9.09 9.36

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

1 Data adjusted for splits and stock dividends.

2 Q3 2019 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 12,087,000,000 ÷ 711,714,480 = 16.98

3 Closing price as at the filing date of Celgene Corp. Quarterly or Annual Report.

4 Q3 2019 Calculation
P/BV ratio = Share price ÷ BVPS
= 108.03 ÷ 16.98 = 6.36

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Celgene Corp. P/BV ratio decreased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.